Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? by Vuilleumier, Nicolas et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density
lipoproteins?
Vuilleumier, Nicolas; Dayer, Jean-Michel; von Eckardstein, Arnold; Roux-Lombard, Pascale
Abstract: Apolipoprotein A-1 (apoA-1) is the principal protein fraction of high-density lipoprotein (HDL),
conferring to the latter many of its pleiotropic atheroprotective functions. After its effect on cholesterol
efflux, the second most studied feature of apoA-1 is its anti-inflammatory property. In addition, it
interferes with lipid peroxidation and innate immune receptors. These anti-inflammatory effects are due
to various properties, in particular the ability to inhibit the transendothelial migration of immune cells by
reducing integrin expression, to inhibit monocyte activation and cytokine production induced by T-cell
contact, to inhibit lipid peroxidation and to interfere with innate immune receptors. Recent studies have
demonstrated that during chronic systemic inflammation HDL could lose some of its atheroprotective
functions and become dysfunctional or even proinflammatory. Recent evidence suggests that specific
post-translational modifications of apoA-1 transform this genuine anti-inflammatory molecule into a
proinflammatory one. The structural changes include chlorination, nitration and carbamylation of amino
acids by myeloperoxidase, oxidation by reactive carbonyls, as well as glycation. Humoral autoimmunity
to apoA-1 and HDL has been reported in populations at high cardiovascular risk and constitutes another
emerging mechanism contributing to the loss of functions of apoA-1 and HDL. The fact that in recent
trials cholesteryl ester transfer protein inhibitors (torcerapib and dalcetrapib) have unfortunately failed to
prevent cardiovascular disease despite increasing cholesterol efflux in vitro and HDL levels in vivo, further
highlights the clinical importance of understanding the mechanisms driving apoA-1 and HDL towards
pro- or anti-inflammatory molecules. These findings should not affect current dyslipidaemia management
guidelines.
DOI: 10.4414/smw.2013.13781
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-82118
Published Version
Originally published at:
Vuilleumier, Nicolas; Dayer, Jean-Michel; von Eckardstein, Arnold; Roux-Lombard, Pascale (2013). Pro-
or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Medical Weekly,
143:w13781. DOI: 10.4414/smw.2013.13781
Review article: Current opinion | Published 25 May 2013, doi:10.4414/smw.2013.13781
Cite this as: Swiss Med Wkly. 2013;143:w13781
Pro- or anti-inflammatory role of apolipoprotein
A-1 in high-density lipoproteins?
Nicolas Vuilleumiera,b, Jean-Michel Dayerc, Arnold von Eckardsteind, Pascale Roux-Lombarda,e
a Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Switzerland
b Department of Human Protein Science, Faculty of Medicine, Geneva, Switzerland
c Faculty of Medicine, Centre Médical Universitaire, Geneva, Switzerland
d Institute of Clinical Chemistry, University and University Hospital Zurich, and Zurich Center of Integrative Physiology, Switzerland
e Division of Immunology and Allergy, Department of Internal Medicine, Geneva University Hospitals, Geneva, Switzerland
Summary
Apolipoprotein A-1 (apoA-1) is the principal protein frac-
tion of high-density lipoprotein (HDL), conferring to the
latter many of its pleiotropic atheroprotective functions.
After its effect on cholesterol efflux, the second most stud-
ied feature of apoA-1 is its anti-inflammatory property. In
addition, it interferes with lipid peroxidation and innate im-
mune receptors. These anti-inflammatory effects are due
to various properties, in particular the ability to inhibit the
transendothelial migration of immune cells by reducing in-
tegrin expression, to inhibit monocyte activation and cy-
tokine production induced by T-cell contact, to inhibit lipid
peroxidation and to interfere with innate immune receptors.
Recent studies have demonstrated that during chronic sys-
temic inflammation HDL could lose some of its atheropro-
tective functions and become dysfunctional or even proin-
flammatory. Recent evidence suggests that specific post-
translational modifications of apoA-1 transform this genu-
ine anti-inflammatory molecule into a proinflammatory
one. The structural changes include chlorination, nitration
and carbamylation of amino acids by myeloperoxidase, ox-
idation by reactive carbonyls, as well as glycation. Humor-
al autoimmunity to apoA-1 and HDL has been reported in
populations at high cardiovascular risk and constitutes an-
other emerging mechanism contributing to the loss of func-
tions of apoA-1 and HDL. The fact that in recent trials cho-
lesteryl ester transfer protein inhibitors (torcerapib and dal-
cetrapib) have unfortunately failed to prevent cardiovascu-
lar disease despite increasing cholesterol efflux in vitro and
HDL levels in vivo, further highlights the clinical import-
ance of understanding the mechanisms driving apoA-1 and
HDL towards pro- or anti-inflammatory molecules. These
findings should not affect current dyslipidaemia manage-
ment guidelines.
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Introduction
Apolipoprotein A-1 (apoA-1) constitutes the principal pro-
tein fraction of high-density lipoprotein (HDL) whose pro-
tective role in the cardiovascular system derives to a great
extent from the inverse relationship between HDL-cho-
lesterol and apoA-1 plasma concentrations, and a risk of
myocardial infarction [1]. The atheroprotective role of
HDL in the cardiovascular system has been attributed to its
pleiotropic effects, including reverse cholesterol transport,
vasodilatation, and antithrombotic, anticoagulant and anti-
inflammatory effects [2]. Mirroring those versatile prop-
erties, mass spectrometry analyses revealed that HDL en-
compasses very heterogeneous macromolecular complexes
of lipids and proteins. Only one-third of the up to 80 differ-
ent proteins identified in HDL is dedicated to lipid trans-
port. The remaining proteins are either acute-phase pro-
teins, proteases, antioxidant or antithrombotic enzymes, or
proteins involved in complement regulation [3].
As well as being the principal protein fraction of HDL and
a limiting factor for HDL formation, apoA-1 per se has
many of the HDL-related atheroprotective properties [4].
Apart from its pivotal role in reverse cholesterol transport
(RCT), where it induces cholesterol efflux via an aden-
osine triphosphate (ATP) binding cassette transporter and
activates lecithin:cholesterol acyltransferase (LCAT) [5],
the second best-studied property of apoA-1 is its mitigating
effect on inflammation through several pathways [2–4].
However, there is a growing body of evidence that both
acute and chronic inflammatory conditions induce post-
translational modifications of apoA-1. These, in turn, not
only dampen the functions regulating lipid homoeostasis
and the anti-inflammatory properties of HDL/ApoA-1, but
even turn it into a proinflammatory molecule [4].
Thus, HDL and apoA-1 appear to contribute to host de-
fence against many biological and chemical hazards.
However, analogous to failing or erroneous host defences
through leukocytes and their humoral mediators, the pro-
tective activities of HDL can be compromised and made
to fail, or even perverted to harm. The literature regarding
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apoA-1 is complex and often blurred by the fact that bio-
logical activities are frequently attributed to apoA-1 alone,
to apoA-1 in association with different lipids or even to
HDLs. Therefore, the aim of the present paper is to review
specifically the pathways by which apoA-1 per se or as
part of HDL acts as an anti-inflammatory molecule, and
to analyse the translational and post-translational modifica-
tions to apoA-1 that could lead to a proinflammatory phen-
otype. Several natural apoA-1 variants have been described
and some are characterised by alterations in lipid binding,
LCAT activation and cholesterol efflux stimulation in vitro,
as well as defective HDL formation in vivo. However, these
are out of the scope of this review, and will not be discussed
here.
Structure and biology of
apolipoprotein A-1
Human apoA-1 is a 28-kD protein with 243 amino acid
residues encoded by the apolipoprotein multigene super-
family located on chromosome 11q23 [6]. The protein is
synthesised as a preprosequence of apoA-1 (24 amino acid
residues longer), primarily by hepatocytes in the liver and
also by enterocytes. The largest part of its secondary struc-
ture consists of class A amphipathic α-helices separated
by proline hinges. In these helices, apolar residues occupy
one face whereas polar residues occupy the other face,
and positively charged lysine and arginine residues separ-
ate the two faces of the helix. This amphipathic structure
allows the interaction of apoA-1 with lipids through its hy-
drophobic faces and with the aqueous phase through its
hydrophilic faces. The proline hinges confer a high ster-
ic flexibility on the apoA-1 molecule, allowing important
conformational changes needed to occupy both discoidal
and spherical HDL particles of different sizes [7].
Upon maturation, HDL undergoes conformational changes
accompanied by important functional changes, enabling in-
teraction with a wide range of different proteins including
ATP binding cassette transporters A1 (ABCA1) and G1
(ABCG1), as well as LCAT and scavenger receptor B1
(SR-B1), which are expressed mostly by hepatocytes and
macrophages [8–10].
Lipid-free apoA-1 represents up to 10% of circulating
apoA-1 [9], which is present in plasma in normal condi-
tions at a concentration of 90–250 mg/dl, slightly higher in
women than in men. In pathological conditions apoA-1 be-
haves as a negative (“reverse”) acute-phase protein, that is,
a protein whose level is lowered by more than 25% dur-
ing the acute-phase response and thought to be displaced
by serum amyloid A (SAA) which is a “positive” acute-
phase protein [11]. However, it was demonstrated subse-
quently that during the acute-phase response, proinflam-
matory cytokines increase the expression of SAA, while
simultaneously decreasing the expression of apoA-1 and
paraoxonase 1 (PON-1), which suggests that the reduction
in apoA-1 during the acute-phase response is not only due
to physical displacement of apoA-1, but to inverse tran-
scriptional regulation in the liver [12].
Site-directed mutagenesis studies resulted in the identifica-
tion of structural domains which specifically modulate the
functionalities of apoA-1. So far, most reports have dealt
with the effects of lipid-free apoA-1 and apoA-1-related
mimetic peptides on cholesterol efflux models mediated by
ABCA1 as well as LCAT activation [9], for which the C-
terminal (amino acid residues (aa): 187‒243) and central
domains (aa: 143‒165), respectively, are important [13].
The N-terminal part of lipid-free apoA-1 (aa: 1‒98) has
been shown to be essential for stabilising its lipid-free con-
formation, as well as for lipid interaction [14–16]. Further-
more, stabilising the α-helix of apoA-1 mimetic peptides
translated into higher cholesterol efflux efficacy, further
confirming that the conformational state of apoA-1 is cru-
cial for its function in regard to cholesterol efflux [17].
ApoA-1 as an anti-inflammatory
molecule
HDLs have been considered to be anti-inflammatory mo-
lecules for 20 years [18]. However, whether these effects
are mainly due to the lipid (for example, sphingos-
ine-1-phosphate) or the protein constituents of HDL
(apoA-1, but also quantitatively minor proteins such as
paraoxonase (PON) or clusterin) is still a matter of debate.
In the following paragraphs, we will review only the spe-
cific anti-inflammatory properties of HDL/apoA-1.
Inhibition of transendothelial migration of
immunocompetent cells
In the mid-nineties, apoA-1 was observed to display anti-
inflammatory properties by inhibiting the cytokine-induced
expression of cell adhesion molecules such as vascular
cell adhesion molecule-1 (VCAM-1), intercellular adhe-
sion molecule-1 (ICAM-1) and E-selectin, which are key
players in diapedesis of immunocompetent cells from the
circulation into the artery wall [19]. Since the latter phe-
nomenon is considered to be one of the earliest events
in atherogenesis, those seminal findings raised the pos-
sibility that apoA-1 could represent an innovative thera-
peutic alternative for preventing atherosclerosis at an early
stage. They also provided initial evidence for an atheropro-
tective role of apoA-1 independent of cellular cholesterol
homeostasis regulation. Later on, the same group demon-
strated that apoA-1 or phospholipids per se were not suf-
ficient to exert the anti-inflammatory properties of lipid-
poor apoA-1, so that for optimal function both must coexist
on one particle. In line with this, the shape of
apoA-1containing HDLs also influences the anti-inflam-
matory response, spherical apoA-1-containing HDLs being
more anti-inflammatory than discoidal ones [19]. Those
results were the first to indicate a significant role of the
conformational state of apoA-1 and HDLs in ensuring the
optimal mediation of their anti-inflammatory effects. After-
wards, it was shown that HDL/apoA-1 modulates the
cytokine-induced integrin expression by activated en-
dothelial cells, as extensively reviewed elsewhere [20].
ApoA-1 has been shown to inhibit both shear stress and
phorbol-12 myristate 13-acetate (PMA) induced monocyte
expression of CD11b, one of the integrins, complementary
to VCAM-1 and ICAM-1, involved in the early stages of
transendothelial migration. In this study, the dose-depend-
ent inhibition of CD11b expression was accompanied by
decreased transendothelial migration of monocytes toward
Review article: Current opinion Swiss Med Wkly. 2013;143:w13781
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 12
chemotactic agents such as monocyte chemoattractant pro-
tein-1 (MCP-1). This activity was strongly dependent on
ABCA1, but independent of SR-B1 signalling [21]. Those
results confirmed and extended a previous observation that
HDL inhibits LDL-induced MCP-1 production in mono-
cytes as well as their subsequent transendothelial diaped-
esis [22]. Further insight into the molecular mechanisms
underlying this phenomenon was gained from the observa-
tion that apoA-1 interaction with ABCA1 promoted signal
transducer and activator of transcription (STAT-3) activa-
tion through janus kinase (JAK) 2, which ultimately abol-
ished the lipopolysaccharide (LPS) induced proinflammat-
ory response (such as interleukin (IL) 1β, IL-6, and tumour
necrosis factor alpha (TNF-α) production by monocytes),
without affecting cholesterol efflux [23]. Altogether, these
results suggested that ABCA1 is not only involved in cho-
lesterol metabolism, but also modulates the anti-inflam-
matory response of cells to apoA-1.
The charge and size of the hydrophobic face of synthetic
apoA-1 peptides are major factors affecting their anti-in-
flammatory properties. More specifically, inhibition of
VCAM-1 expression was maximised by increasing the hy-
drophobic face size and the number of positively charged
residues. Inhibition of CD11b expression in monocytes in-
creased with asymmetry and hydrophobicity, but dimin-
ished with increasing numbers of positively charged
residues, further emphasising the importance of apoA-1
conformation to the deployment of its anti-inflammatory
properties [19, 24].
In conclusion, in specific conformations, apoA-1 can in-
hibit transendothelial migration of immunocompetent cells,
both by blocking the production of chemotactic cytokines
by monocytes and by impeding the expression by en-
dothelial and monocytic cells of integrins required for effi-
cient diapedesis in response to chemotactic agents.
Inhibition of T-cell contact-mediated monocyte
activation
Once transendothelial migration of inflammatory cells has
occurred, the interaction between monocyte-macrophages
and T cells represents another important step in modulating
the microenvironment of the chronic inflammatory re-
sponse. Indeed, direct contact between activated T cells
and monocytes/macrophages is a major driver for the pro-
duction of several inflammatory cytokines, such as IL-1β,
IL-6, IL-8, MCP-1 and TNF-α, which are well known for
being involved in atherogenesis and tissue destruction [25,
26]. ApoA-1 has been shown to inhibit contact-mediated
monocyte stimulation and the subsequent production of
IL-1β and TNF-α. Although the exact mechanisms of ac-
tion are not fully elucidated yet, the authors suggested
that apoA-1 blocks T-cell/monocyte interactions at the T
cell level [25]. This conclusion is in accordance with pre-
vious work suggesting the presence of a specific, but as
yet unidentified, HDL binding site on human lymphocytes
[27]. Additional studies in this model of cell-cell interac-
tion demonstrated that HDL/apoA-1 inhibits T-cell contact-
activated specific proinflammatory gene expression in
monocytes [28]. In contrast, HDL/apoA-1 does not affect
or inhibit - or only to a small extent - the expression of mo-
lecules displaying anti-inflammatory and regulatory func-
tions such as IL-1 receptor antagonist (IL-1Ra). Microarray
analysis shows that 437 out of 54,675 probe sets were en-
hanced in monocytes activated by contact with stimulated
T cells of which 164 (i.e. 38%) were inhibited in the pres-
ence of HDL. These results were validated using real-time
polymerase chain reaction (qPCR) [28].
These in-vitro observations were confirmed in vivo in vari-
ous chronic and acute pathological conditions. For ex-
ample, immunohistochemistry on synovial biopsies from
rheumatoid arthritis patients revealed that apoA-1 was con-
sistently present in inflamed synovial tissue that contained
infiltrating T cells and macrophages, but was absent from
noninflamed tissue samples obtained from treated patients
and from normal subjects. ApoA-1 was not present in syn-
ovium from patients in apparent remission, which suggests
that it has a specific role during phases of disease activity
[29]. On the other hand, HDL/apoA-1 was markedly re-
duced in patients admitted to an intensive care unit for
systemic inflammatory response syndrome. Patients with
an exacerbated inflammatory state had significantly lower
plasma levels of apoA-1 than those whose inflammation
was not exacerbated, which suggests a protective role of
apoA-1. Moreover, a correlation was established between
the levels of apoA-1 in patients’ sera and their in-vitro in-
hibitory effect on the release of IL-1β by T-cell-stimulated
monocytes [30]. There is currently no information avail-
able as to the conformational requirements for apoA-1 to
modulate the cell-cell contact inhibition. However, a spe-
cific blocking antibody to apoA-1 proved to interfere with
the inhibitory action of HDL [30].
Inhibition of lipid peroxidation
Another important step in inflammation and atherogenesis
is the uptake of lipid peroxidation products by macro-
phages, with oxidised low-density lipoproteins (oxLDL)
being key players in early and late stages of atherogenesis
[31–32]. The proatherogenic properties of oxLDLs consist
mostly in fostering sterile inflammation through the activ-
ation of various innate immune receptors that trigger nu-
merous signalling pathways, as extensively reviewed else-
where [31–32]. In 1979 it was demonstrated that HDLs
are able to inhibit LDL oxidation [33]. Subsequent studies
demonstrated that this feature was related to the presence
of apoA-1 on HDL molecules, and that it could be fully re-
produced by apoA-1 mimetic peptides [2]. This antioxidant
property of apoA-1 is believed to be mainly, but not exclus-
ively, due to PON-1, an enzyme associated with apoA-1
and known to prevent different kinds of lipid peroxida-
tion [34]. Preserving the proline bridge on bihelical apoA-1
synthethic peptides was found to be detrimental to the an-
tioxidant properties of the peptides, whereas modifications
of the charge, the hydrophobicity, or the size of hydro-
phobic face had only a limited impact on the antioxidant
capacity of those peptides [24].
Considering that antioxidant agents failed to prevent cardi-
ovascular disease in randomised controlled trials, the clin-
ical benefit of these antioxidant properties remains to be
determined [35].
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Modulation of the innate immune response and Toll-
like receptors
The innate immune response represents the first line of
defence against infectious agents and modified autoanti-
gens (modified/oxidised lipids and apoptotic cells), allow-
ing their rapid clearance through lysosomal degradation,
and at the same time drives the development of a more
specific and efficient adaptive response. The innate im-
mune system consists of both cellular and humoral com-
ponents. Major cellular components are neutrophils, mono-
cyte/macrophages, natural killer (NK) and lymphokine-ac-
tivated killer (LAK) cells, and eosinophils. The humoral
counterpart is mostly represented by the pentraxin family,
the complement system and various cytokines. Three main
classes of innate immune receptors have been described:
Toll-like receptors (TLRs), scavenger receptors (SRs) and
Nod-like receptors (NLRs). The former two are considered
important mediators of the immune-mediated inflammation
that characterises atherogenesis [36–37]. Both HDL and
apoA-1 have been shown to modulate either directly or in-
directly the signalling of the innate immune system at dif-
ferent levels.
As early as 1979, the effect of HDL on the innate immune
system proved to reduce LPS toxicity in vivo [38]. In vitro,
LPS stimulates substantially more IL-1 mRNA and cell-as-
sociated IL-1 protein when monocytes are stimulated with
LPS alone than with LPS-HDL [39]. This activity was later
attributed to the fact that HDL sequesters LPS and thereby
prevents the transduction of the proinflammatory cascade
through TLR4/CD14 complex interaction [40]. By using
several apoA-1 mutants, apoA-1 was found to be the key
component of HDL-related LPS neutralisation. Indeed, the
N-terminal region (aa: 52‒74) of apoA-1 was identified as
being specific to this effect, without affecting cholesterol
efflux from macrophages [41].
As well as preventing upstream TLR4 activation by imped-
ing the interaction with its ligand, apoA-1 has also been
shown to inhibit TLR4 signalling directly by impeding its
transport into lipid rafts [42]. Although controversial, re-
cent work identified apoA-1 not only as a circulating mo-
lecule, but also as a cellular molecule expressed in low
amounts by macrophages. It has been localised in lipid rafts
and in the vicinity of ABCA1 [43]. These authors repor-
ted that, by its spatially close association, apoA-1 stabil-
ises the membrane expression of ABCA1. Moreover, sup-
pressed endogenous apoA-1 was associated with increased
expression of TLR4 at the mRNA level [43]. According
to these findings, endogenous and circulating apoA-1 can
modulate TLR4 signalling. To the best of our knowledge,
such evidence is currently lacking for other TLRs.
SRs were the first innate immune receptors known to have
apoA-1 as one of their numerous ligands. Among them,
SR-B1 is known to be an important effector of the various
anti-inflammatory functions of HDL. Indeed, apoA-1/SR-
B1 interaction is crucial for cholesterol efflux [22], nitric
oxide synthesis, glucocorticoid synthesis and TLR4 sig-
nalling [9–10, 44]. However, as discussed later in the proin-
flammatory section, apoA-1 interaction with SRs could
have contradictory effects on inflammation control.
Another important mechanism for the functionality of in-
nate immune receptors is their targeting on functional lipid
rafts, which allows their interaction with other coreceptors
for the optimal activation downstream of specific sig-
nalling pathways. Accordingly, the integrity of lipid rafts
has been shown to be crucial for appropriate proinflam-
matory TLR signalling [45]. In this respect, apoA-1 has
been shown to induce cholesterol depletion from lipid rafts,
thereby decreasing TLR4 functionality and inhibiting LPS-
induced inflammatory responses [46].
Modulation of the adaptive immune response
Because lipid rafts on antigen presenting cells (APCs) also
concentrate major histocompatibility complex (MHC) class
2 molecules, which are known to play a crucial part in
T-lymphocyte activation [47], it can be hypothesised that
apoA-1 may have a significant impact on the adaptive as-
pect of the immune response. Nevertheless, to the best of
our knowledge, this appealing hypothesis has never been
formally validated.
Among other major players of the immune system, reg-
ulatory T cells (Tregs) are important components of the
adaptive immune response, acting to maintain self-toler-
ance. Tregs suppress the activation of T cells by either a
contact-dependent process involving APCs or secretion of
anti-inflammatory cytokines such as IL-10 and transform-
ing growth factor beta (TGF-β) [48]. The absence of, or
defects in, Tregs can lead to inflammatory disease such as
autoimmune disorders and atherosclerosis [48].
ApoA-1-/- x LDL-receptor-/- double knock-out mice exhibit
an autoimmune phenotype. In this model, administration of
exogenous apoA-1 was found to prevent the differentiation
of T cells into a proinflammatory Th17 phenotype, and to
increase the Treg population. These anti-inflammatory ef-
fects at the cellular level were accompanied macroscopic-
ally by the restoration of a close-to-normal phenotype of
skin architecture, morphology and composition [49]. The
mechanisms underlying the beneficial effect of apoA-1 ad-
ministration on Treg function are still unknown.
As summarised in table 1, apoA-1 acts as a pleiotropic anti-
inflammatory agent by modulating the inflammatory re-
sponse at the prereceptor, receptor and postreceptor levels,
mainly on innate APCs. It also appears to act on the ad-
aptive compartment by decreasing Th17 polarisation and
promoting Treg expansion. As a consequence, apoA-1 can
inhibit the production of proinflammatory cytokines, and
the cell contact-mediated inflammatory response. It also
prevents the generation of self-modified antigens by in-
hibiting the formation or persistence of lipid peroxidation
products. Together, these effects have the potential ulti-
mately to translate into reduced chemotaxis, diapedesis and
inflammatory activity of immunocompetent cells at the site
of inflammation.
ApoA-1 as a proinflammatory
molecule
In both acute and chronic inflammation, HDL can become
proinflammatory [4], a phenomenon initially explained by
the replacement of apoA-1 by serum amyloid A (SAA) pro-
tein, ceruloplasmin and haptoglobin [4], with SAA repres-
enting up to 87% of HDL proteins [50]. These SAA-con-
taining HDLs may be retained in the arterial intima through
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facilitated interaction with vascular proteoglycans, and are
thus more extensively exposed to oxidative modifications.
Recent studies reviewed in the next paragraphs demon-
strate that other translational and post-translational modi-
fications can turn apoA-1 into a proinflammatory molecule.
Amyloidosis as a human paradigm to study the
pathogenicity of translational and post-translational
apoA-1 modifications
ApoA-1 is involved in two forms of amyloidosis, a disease
affecting vital organs such as kidney, liver and heart; amyl-
oidosis therefore constitutes a suitable human paradigm to
investigate the pathophysiological consequences of apoA-1
modifications, both at the translational and post-transla-
tional levels. In both nonhereditary and hereditary
amlyoidosis, modifications of apoA-1 (either through ox-
idation or proteolysis in the former, or through mutations
Figure 1
Mechanisms of apolipoprotein A-1 (apoA-1) carbamylation.
MPO = myeloperoxidase
in the latter, form of the disease) lead to the formation of
amyloid fibrils/complexes found in various organs and in
atherosclerotic plaques [51]. Although their involvement
in inflammation and atherosclerosis is just beginning to be
elucidated, it seems that newly formed amyloid complexes,
fibrils or β-sheets are capable of inhibiting reverse choles-
terol transport [52] and generate a strong proinflammatory
response through the signalling receptor of advanced glyc-
ation end products (AGE) [53]. Nevertheless, those in vitro
observations have not yet been validated by experimental
evidence in vivo.
Post-translational apoA-1 modifications
ApoA-1 modifications driven by myeloperoxidase
Functionally relevant post-translational modifications of
apoA-1 include chlorination, nitration and oxidation of tyr-
osine residues, which are catalysed by myeloperoxidase
(MPO). ApoA-1 and HDL derived from patients with car-
diovascular disease had a significantly higher content of
MPO-dependent oxidative modifications, which are func-
tionally associated with a reduced capacity of apoA-1 to
bind to ABCA1 and to induce ABCA1-mediated choles-
Figure 2
The pro- and anti-inflammatory role of apolipoprotein A-1 (apoA-1) /
high-density lipoprotein (LDL).
CV = cardiovascular; IC = immune complexes; LDL = low-density
lipoprotein; PTM = post-translational modifications; TLR = Toll-like
receptor.
Table 1: Summary of apolipoprotein A-1 (apoA-1) related anti-inflammatory properties in relation with apoA-1 specific regions and conformation.
ApoA-1 anti-inflammatory properties ApoA-1 specific region Conformation-dependent Reference
number
LPS binding N-terminal
(aa:52‒74)
Unknown [38–40]
ABCA1 interaction C-terminal Yes, hydrophobic regions close to negatively charged
cluster
[8, 9, 13]
SR-B1 interaction C-terminal Yes, positively charged residues [10, 24]
TLR4 expression/signalling inhibition No specified Unknown [41–43, 45, 46]
Inhibition of endothelial integrin expression (VCAM1,
ICAM1, E-selectin)
Not specified Yes, depends on the hydrophobic face size and the
number of positively charged residues
[19–20, 24]
Inhibition of monocytes integrin expression (CD11b) Not specified, but ABCA1
Dependent; C-terminal?
Yes, depends on the asymmetry and hydrophobic face
size, and the negatively charged residues
[21, 22]
Lipid peroxidation Not specified Yes, depends on the presence of the proline bridge,
determining the angle between helixes
[33, 34, 24]
T cell/Monocyte interaction Not specified Unknown [25, 26, 28]
Increase Treg differentiation Not specified Unknown [49]
Aa = amino acid residues; ABC = ATP binding cassette transporter; ATP = adenosine triphosphate; ICAM = intercellular adhesion molecule; LPS = lipopolysaccharide; SR
= scavenger receptor; TLR = Toll-like receptor; Treg = regulatory T cell; VCAM = vascular cell adhesion molecule.
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terol efflux [54]. Physiologically relevant concentrations of
MPO may generate dysfunctional HDLs characterised by
a reduced cholesterol efflux capacity [55]. These findings
were the first to demonstrate a causal link between specif-
ic apoA-1 modifications inducing dysfunctional HDL and
a proinflammatory status through a specific MPO-driven
pathway.
Another post-translational HDL modification driven by
MPO reported recently is carbamylation [56], whose clin-
ical relevance to cardiovascular disease, especially in renal
failure patients, is well established [57]. Protein carbamyl-
ation is mediated by cyanate, which is in turn produced
either by MPO or urea decomposition (fig. 1). Carbamyl-
ated apoA-1 was found to be significantly increased in ad-
vanced atherosclerotic lesions when compared with ves-
sels with early lesions, but no such differences in plasma
HDL levels were noted between those groups. The authors
also demonstrated that in-vitro carbamylation of apoA-1 in-
hibits SR-B1 but not ABCA1-mediated cholesterol efflux,
leading to a marked cholesterol accumulation in THP-1
macrophages [57]. Those results constitute further eviden-
ce of apoA-1 modifications affecting HDL atheroprotective
properties.
ApoA-1 modifications driven by reactive carbonyls
Reactive carbonyls can also generate specific apoA-1
products derived from oxidation/glycation. Reactive car-
bonyls are generated either by carbohydrate oxidation,
which gives rise to proinflammatory AGE molecules [58],
or lipid peroxidation, which produces advanced lipoxid-
ation end products (ALE) [58, 59]. Both ALE and AGE
have been associated with diabetes and cardiovascular dis-
ease [58, 59], and were shown to modify native apoA-1
in different but specific ways. Nobecourt and co-workers
demonstrated that, after exposure to glycation and sub-
sequent incorporation into discoidal reconstituted HDLs,
apoA-1 lost its capacity to activate LCAT. This loss was as-
sociated with modifications of arginine, lysine and trypto-
phan residues [60]. Recently, the same group showed that
apoA-1 glycation induced by methylglyoxal in vitro or in
vivo resulted in apoA-1 failing to inhibit both the infiltra-
tion of neutrophils into the intima of rabbit carotid arteries
and the expression of ICAM-1 and VCAM-1 in endotheli-
al cells. This effect was accompanied by increased nuclear
NF-κB translocation when compared with native apoA-1,
and a reduced ability to inhibit the formation of reactive
oxygen species (ROS) [61]. When exposed to methylgly-
oxal, reconstituted HDLs displayed the same loss of func-
tion of their anti-inflammatory properties when compared
with lipid-free apoA-1, suggesting that those apoA-1 modi-
fications driven by carbonyl-reactive species can generate
dysfunctional HDL in terms of cholesterol efflux, and anti-
inflammatory and antioxidant properties. These appealing
in-vitro findings still need to be validated in relevant hu-
man in vivo models.
Humoral autoimmune response to apoA-1/HDL
In humans, low apoA-1 concentrations are associated not
only with increased risk for cardiovascular disease, but also
autoimmune diseases, such as rheumatoid arthritis and sys-
temic lupus erythematosus (SLE) [29]. In accordance with
these observations in humans, hypercholesterolaemic mice
lacking plasma apoA-1 display an increased susceptibility
to autoimmunity characterised by enlarged lymph nodes,
cellular activation and proliferation, as well as lipid accu-
mulation [62].
Autoantibodies to apoA-1 have been primarily shown to
be increased in autoimmune conditions associated with in-
creased cardiovascular risk, such as SLE [63, 64], primary
antiphospholipid syndrome [65], and subsequently in pa-
tients with rheumatoid arthritis [66, 67], as well as in pa-
tients suffering from acute coronary syndromes (ACS)
[68–70] and severe carotid stenosis [71]. In ACS and
rheumatoid arthritis patients, high levels of these
autoantibodies were found to predict independently poor
cardiovascular prognosis [67, 72]. From a pathophysiolo-
gical point of view, these autoantibodies elicit a direct
proinflammatory effect through TLR2/CD14 complex sig-
nalling [73] and neutrophil chemotaxis in vitro, as well as
promoting atherogenesis and atherosclerotic plaque vulner-
ability in vivo [71]. Furthermore, these autoantibodies have
also been shown in vitro to act as a positive chronotropic
agent in the presence of aldosterone [72], an effect recently
attributed to a protein kinase A-dependent L-type calcium
channel activation [74].
Furthermore, in some circumstances anti-apoA-1
autoantibodies have been associated with a decrease in
the beneficial anti-inflammatory effects of apoA-1. Indeed,
clinical and animal studies indicate that those autoantibod-
ies impeded some of the HDL-related antiatherogenic
properties, leading to dysfunctional HDLs. In SLE and
primary antiphospholipid syndrome patients, as well as in
lupus-prone mice, the presence of these autoantibodies was
associated with a decrease in the antioxidant properties of
HDL due to decreased PON-1 activity [64, 75, 76], and in-
creased proinflammatory ROS levels [65].
Whether the existence of these apoA-1 antibodies is the
cause or the consequence of the aforementioned apoA-1
modifications is still unclear. In favour of the former hy-
pothesis would be that MPO or apoA-1 modifications me-
diated by reactive carbonyls give rise to neo-epitopes, fol-
lowed by the appearance of autoantibodies. On the other
hand, antibodies may act as oxidative proteins generating a
pro-oxidant microenvironment through their ability to gen-
erate ROS via water oxidation [77]. If this effect optim-
ises the affinity of antibodies for their target [78], it is pos-
sible that such antibody-related oxidative properties could
induce oxidative modifications in their target. In this scen-
ario, autoantibodies to apoA-1/HDL may lead to the forma-
tion of proinflammatory apoA-1/HDLs. Further work is re-
quired to confirm or reject those hypotheses.
Finally, as hormones markedly influence autoimmune dis-
eases, and the oestrogen/androgen balance determines the
synthesis of apoA-1 in the liver [79], it is essential to find
out whether the hormonal environment could modulate the
occurrence of anti-apoA-1 antibodies. All these aspects are
summarised in figure 2.
Conclusions and perspectives
ApoA-1 displays pleiotropic anti-inflammatory properties
by modulating the innate inflammatory response at the
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prereceptor, receptor and postreceptors levels. It also ap-
pears to act on the adaptive compartment by decreasing
Th17 polarisation and promoting Treg expansion. As a
consequence, lipid-free apoA-1 inhibits the production of
proinflammatory cytokines without affecting anti-inflam-
matory cytokines (i.e. IL-1Ra), cell contact-mediated in-
flammatory response, and the generation of self-modified
antigen by inhibiting lipid peroxidation products. Together,
these effects translate into impaired chemotaxis and dia-
pedesis, and decreased pro-inflammatory activity of im-
munocompetent cells at the site of inflammation.
Nevertheless, different groups demonstrated in past years
that specific post-translational modifications of apoA-1
(summarised in table 2) that occur in the context of system-
ic inflammation can transform this genuine anti-inflammat-
ory molecule into a proinflammatory one. Oxidative dam-
age mediated either by myeloperoxidase (MPO) or reactive
carbonyls as well as glycation and MPO-driven carbamyl-
ation appear to be the most important pathways leading to
the transformation of anti-inflammatory apoA-1 into a pro-
inflammatory molecule. Furthermore, humoral autoimmu-
nity to apoA-1 and HDL has been reported in populations
at high cardiovascular risk and may constitute another
mechanism potentially leading to proinflammatory
apoA-1/HDL.
From a clinical perspective, the recent unfortunate failures
of cholesteryl ester transfer protein (CETP) inhibitors
(ILLUMINATE trial for torcetrapib and Dal-Outcomes tri-
al for dalcetrapib) to prevent cardiovascular disease [80,
81] casts doubt on the “HDL-raising hypothesis”. The one-
year cardiovascular mortality increase observed with tor-
cetrapib (prompting study interruption) has been attributed
to aldosterone-related off-target effects of this molecule
and to deleterious effects on endothelial function [82, 83],
but the reasons for the failure of dalcetrapib, devoid of
such deleterious properties, to prevent cardiovascular dis-
ease despite raising HDL levels effectively are still unclear
[81, 84]. The results of ongoing trials involving two other
promising CETP inhibitors (anacetrapib and evacetrapib)
are therefore eagerly awaited before any firm conclusion
can be drawn about the efficacy of these therapeutic agents
to prevent cardiovascular disease. In conclusion, the fail-
ures of CETP inhibitors to prevent cardiovascular disease
despite inducing a sustained HDL increase stress the clin-
ical importance of understanding the mechanisms and the
circumstances driving apoA-1 and HDL towards pro- or
anti-inflammatory molecules. These results also suggest
that in parallel to in-vitro models of cholesterol efflux,
models testing the proinflammatory response should be
highly encouraged in order to determine the potential fu-
ture therapeutic benefit of apoA-1 and apoA-1 mimetic
peptides. Nevertheless, because these hypotheses are cur-
rently without any clinical evidence, and because no con-
sensus exists on how HDL functionality should be de-
termined, no rapid changes in the current management of
dyslipidaemia and cardiovascular risk stratification [85] are
expected to occur.
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Figures (large format)
Figure 1
Mechanisms of apolipoprotein A-1 (apoA-1) carbamylation.
MPO = myeloperoxidase
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Figure 2
The pro- and anti-inflammatory role of apolipoprotein A-1 (apoA-1) / high-density lipoprotein (LDL).
CV = cardiovascular; IC = immune complexes; LDL = low-density lipoprotein; PTM = post-translational modifications; TLR = Toll-like receptor.
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